BiotechTube
Home/Atrogi/Paul Little
PL

Paul Little

CEO

Atrogi

Therapeutic Areas

Metabolic DisordersDiabetesMuscular WastingObesity

Atrogi Pipeline

DrugIndicationPhase
ATR-258Metabolic disorders (e.g., Type 2 Diabetes, Muscular Wasting)Phase 2

Leadership Team at Atrogi

TB
Tore Bengtsson
Founder & CSO
PB
Philip Berglöf
CFO
AL
Anna-Maria Langkilde
CMO
SK
Sofia Karlström
Head of Chemistry and IP
ND
Nodi Dehvari
Head of Biology
ER
Erik Rollman Waara
COO
View full Atrogi profile